Cinctive Capital Management LP Boosts Stock Position in Nurix Therapeutics, Inc. $NRIX

Cinctive Capital Management LP increased its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 64.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 191,015 shares of the company’s stock after acquiring an additional 74,882 shares during the period. Cinctive Capital Management LP’s holdings in Nurix Therapeutics were worth $1,765,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of NRIX. Vanguard Group Inc. boosted its position in Nurix Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 4,488,776 shares of the company’s stock valued at $41,476,000 after buying an additional 23,269 shares during the period. Vestal Point Capital LP increased its position in shares of Nurix Therapeutics by 77.7% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company’s stock worth $22,780,000 after acquiring an additional 874,448 shares during the period. Geode Capital Management LLC raised its stake in shares of Nurix Therapeutics by 9.1% in the second quarter. Geode Capital Management LLC now owns 1,881,960 shares of the company’s stock valued at $21,437,000 after acquiring an additional 157,592 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Nurix Therapeutics by 11.9% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,557,479 shares of the company’s stock valued at $14,391,000 after acquiring an additional 165,841 shares in the last quarter. Finally, Amova Asset Management Americas Inc. boosted its holdings in Nurix Therapeutics by 12.1% in the third quarter. Amova Asset Management Americas Inc. now owns 1,557,479 shares of the company’s stock valued at $14,391,000 after purchasing an additional 168,205 shares during the period.

Analysts Set New Price Targets

NRIX has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and set a $26.00 price objective on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Morgan Stanley set a $36.00 target price on shares of Nurix Therapeutics and gave the company an “overweight” rating in a report on Thursday, January 8th. Wells Fargo & Company decreased their price target on shares of Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Thursday, January 29th. Royal Bank Of Canada boosted their price target on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, January 29th. Finally, Mizuho increased their price objective on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.54.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of the company’s stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the sale, the chief financial officer owned 45,427 shares of the company’s stock, valued at approximately $754,088.20. This represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gwenn Hansen sold 4,895 shares of the firm’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $81,257.00. Following the completion of the transaction, the insider owned 83,672 shares of the company’s stock, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.40% of the company’s stock.

Nurix Therapeutics Trading Up 2.3%

Nurix Therapeutics stock opened at $15.38 on Tuesday. The stock has a 50 day moving average of $16.92 and a two-hundred day moving average of $14.52. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $22.50. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -5.06 and a beta of 1.96.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Wednesday, January 28th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.02. The business had revenue of $13.58 million for the quarter, compared to the consensus estimate of $13.41 million. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. Equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.